$SEER

Nishar Dipchand sold $23K of SEER

Nishar Dipchand sold 10,660 shares of Seer, Inc. (SEER) at $2.18 on 2026-07-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Nishar Dipchand
Published Jul 10, 2026, 10:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SEER
Neutral
high confidence
Mentioned
$SEER
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SEERNeutralLow
01

Why it matters

The newest concrete fact is the reported sale details (shares, price, total value) and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and lack of new company fundamentals make this more of a sentiment datapoint than a catalyst.

03

What to watch

The filing does not disclose reasons for the sale, and the transaction size is modest relative to typical institutional flows, reducing tradable signal.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-10 after the 2026-07-08 sale execution.

Background

The article is a SEC Form 4 insider transaction disclosure for Seer, Inc., reported by director Nishar Dipchand.

Company-level read

Ticker impact

$SEERNeutralHigh confidence
Context

Seer director Nishar Dipchand sold 10,660 shares on 2026-07-08 at $2.1825, totaling $23,265.45, under a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any effect is more about sentiment than new company information.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operating, financial, or regulatory facts about Seer.

Market effects

No clear sector read-through because the disclosure is a single-company insider sale without new guidance or events.

None indicated.

None indicated.

Counterpoint

Insider sales under 10b5-1 can reflect scheduled liquidity needs rather than bearish expectations, so the market may overreact to the headline optics.

Key entities

  • Seer, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Nishar Dipchand

    Director who sold 10,660 shares on 2026-07-08 under a 10b5-1 plan.

Related articles

$SEERMedAI 8/10

Two Revised, Non-Binding Proposals Seek to Acquire All of Seer's Class A Shares

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D. Rhea-AI Summary Seer (Nasdaq: SEER) confirmed receipt of two further revised, unsolicited, non-binding acquisition proposals for all outstanding shares of its Class A common stock. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right.

$SEERMed

Seer Stock Surges 40% After Investor Presentation Highlights AI, Growth Strategy

Seer, Inc. (SEER) shares rose about 39.8% to $2.27 on Monday after the company published an investor presentation ahead of its July 28 annual meeting. Seer cited an AI-driven proteomics strategy, commercialization progress, an expanding installed base, strategic collaborations, about $220M cash with no debt, and a stated $23B proteomics market opportunity by 2034, and urged shareholders to reject activist proposals.

$SEERMed

Seer Shares Rally 30% Following Investor Update Ahead of Annual Meeting (SEER)

Seer, Inc. (NASDAQ:SEER) shares rose about 30% after the company filed an investor presentation ahead of its July 28, 2026 annual meeting. Seer cited a $23B proteomics TAM by 2034, 62% CAGR growth in installed customers since 2021, 36% lower annual cash burn since 2022, ~$220M cash and no debt, and a $50M buyback authorization. A proxy contest is ongoing.